Market revenue in 2024 | USD 255.7 million |
Market revenue in 2035 | USD 1,890.7 million |
Growth rate | 20.1% (CAGR from 2025 to 2035) |
Largest segment | Rybelsus (oral semaglutide) |
Fastest growing segment | Rybelsus (oral semaglutide) |
Historical data | 2018 - 2023 |
Base year | 2024 |
Forecast period | 2025 - 2035 |
Quantitative units | Revenue in USD million |
Market segmentation | Ozempic (semaglutide), Wegovy (semaglutide), Rybelsus (oral semaglutide) |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to semaglutide market will help companies and investors design strategic landscapes.
Rybelsus (oral semaglutide) was the largest segment with a revenue share of 46.77% in 2024. Horizon Databook has segmented the Japan semaglutide market based on ozempic (semaglutide), wegovy (semaglutide), rybelsus (oral semaglutide) covering the revenue growth of each sub-segment from 2018 to 2035.
Japan’s semaglutide market is expanding due to government-backed initiatives for diabetes and obesity management.
The aging population and increasing prevalence of obesity contribute to demand. Retail pharmacies dominate semaglutide distribution, with hospital pharmacies enhancing disease management strategies.
Horizon Databook provides a detailed overview of country-level data and insights on the Japan semaglutide market , including forecasts for subscribers. This country databook contains high-level insights into Japan semaglutide market from 2018 to 2035, including revenue numbers, major trends, and company profiles.
No related statistics found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account